
4SC Investor Relations Material
Latest events

Q2 2024
4SC

Q1 2025
17 Apr, 2025

Q4 2024
28 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 4SC AG
Access all reports
4SC AG is a Germany-based biotechnology company focused on the development of small-molecule drugs for the treatment of cancer. The company’s research centers on epigenetic cancer therapies, particularly those aimed at modulating the immune system and tumor microenvironment. Its operations encompass drug discovery, clinical development, and regulatory activities. 4SC AG is headquartered in Planegg-Martinsried, Germany, and its shares are listed on the XETRA.